<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628234</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001</org_study_id>
    <secondary_id>2020-A00439-30</secondary_id>
    <nct_id>NCT04628234</nct_id>
  </id_info>
  <brief_title>Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site (RESPECT)</brief_title>
  <acronym>RESPECT</acronym>
  <official_title>Follow-up of Actual Patient Care Site Two Months After Hospitalisation Compared With Their Expressed Choice Regarding Subsequent Care Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non randomized, monocentric, descriptive, transversal and prospective study. The&#xD;
      purpose of this study is to assess the compliance with patient expressed choice regarding&#xD;
      subsequent care and death -if occured- site (at hospital or at home) after hospitalisation&#xD;
      for terminally ill patients with an onco-hematologic solid tumor in palliative care and to&#xD;
      identify reasons for potential non-compliance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will reply to two questionnaires, at inclusion and two months after inclusion.&#xD;
      Primary care physician will also be contacted by phone to reply to two questionnaires, at&#xD;
      inclusion and two months after inclusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2020</start_date>
  <completion_date type="Actual">January 9, 2021</completion_date>
  <primary_completion_date type="Actual">January 9, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients for which their choice of care and death -if occured- site (at hospital or at home) is respected.</measure>
    <time_frame>2 months after inclusion</time_frame>
    <description>Patients will fill out a questionnaire at inclusion and 2 months after inclusion if they are still alive. Death site will be collected from primary care physician if patient died.&#xD;
The patient expressed choice regarding subsequent care and death site collected in the first questionnaire at inclusion will be compared to the situation at 2 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new hospitalisations occuring after inclusion, if any.</measure>
    <time_frame>2 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of new hospitalisations occuring after inclusion, if any.</measure>
    <time_frame>2 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for new hospitalisations occuring after inclusion, if any.</measure>
    <time_frame>2 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">53</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Tumor, Solid</condition>
  <arm_group>
    <arm_group_label>Patients with an onco-hematologic solid tumor in palliative care</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an onco-hematologic solid tumor in palliative care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 18 years old&#xD;
&#xD;
          -  Patients with onco-hematologic solid tumor (locally advanced or metastatic) against&#xD;
             which specific and systemic treatments are outdated or have been stopped (symptomatic&#xD;
             palliation with radiotherapy is allowed)&#xD;
&#xD;
          -  Patients admitted in full hospitalisation&#xD;
&#xD;
          -  Patients able to speak, read and understand French&#xD;
&#xD;
          -  Patients able to answer the phone&#xD;
&#xD;
          -  Signed informed consent from the patient&#xD;
&#xD;
          -  Patients must have a social security coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 18 years old or incapable person ≥ 18 years old&#xD;
&#xD;
          -  Patients admitted for any surgical intervention&#xD;
&#xD;
          -  Patients unable to read French&#xD;
&#xD;
          -  Patients whose physical or psychological condition do not allow them to answer orally&#xD;
             or in writing&#xD;
&#xD;
          -  Patients deprived of liberty&#xD;
&#xD;
          -  Patients placed under judicial protection&#xD;
&#xD;
          -  Women that are pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

